Skip to main content
To KTH's start page To KTH's start page

Publications

The 50 latest publications

[1]
U. Marking et al., "Humoral immune responses to the monovalent xbb.1.5-adapted bnt162b2 mrna booster in sweden," The Lancet - Infectious diseases, vol. 24, no. 2, pp. e80-e81, 2024.
[2]
J. Yan et al., "Distinct roles of vaccine-induced SARS-CoV-2-specific neutralizing antibodies and T cells in protection and disease," Molecular Therapy, vol. 32, no. 2, pp. 540-555, 2024.
[3]
J. Scheffel et al., "Calcium-dependent affinity ligands for the purification of antibody fragments at neutral pH," Journal of Chromatography A, vol. 1694, pp. 463902, 2023.
[4]
A. Abouzayed et al., "The GRPR Antagonist [Tc-99m]Tc-maSSS-PEG(2)-RM26 towards Phase I Clinical Trial : Kit Preparation, Characterization and Toxicity," Diagnostics, vol. 13, no. 9, pp. 1611, 2023.
[5]
O. Bragina et al., "Direct Intra-Patient Comparison of Scaffold Protein-Based Tracers, [99mTc]Tc-ADAPT6 and [99mTc]Tc-(HE)3-G3, for Imaging of HER2-Positive Breast Cancer," Cancers, vol. 15, no. 12, 2023.
[6]
U. Marking et al., "Correlates of protection and viral load trajectories in omicron breakthrough infections in triple vaccinated healthcare workers," Nature Communications, vol. 14, no. 1, 2023.
[7]
M. Möller et al., "An easy-to-use high-throughput selection system for the discovery of recombinant protein binders from alternative scaffold libraries," Protein Engineering Design & Selection, vol. 36, 2023.
[8]
O. Bladh et al., "Mucosal immune responses following a fourth SARS-CoV-2 vaccine dose," The Lancet Microbe, vol. 4, no. 7, pp. 488, 2023.
[9]
U. Marking et al., "7-month duration of SARS-CoV-2 mucosal immunoglobulin-A responses and protection," The Lancet - Infectious diseases, vol. 23, no. 2, pp. 150-152, 2023.
[10]
M. Wolf-Watz et al., "Calcium-dependent protein folding in a designed molecular switch," Biophysical Journal, vol. 122, no. 3S1, 2023.
[11]
J. Nilvebrant, S. Hober and S. Kanje, "Ligand and use thereof," us 11820802 (2023-11-21), 2023.
[12]
J. Scheffel et al., "Design of an integrated continuous downstream process for acid-sensitive monoclonal antibodies based on a calcium-dependent Protein A ligand," Journal of Chromatography A, vol. 1664, pp. 462806-462806, 2022.
[13]
L. Blixt et al., "Covid-19 in patients with chronic lymphocytic leukemia : clinical outcome and B- and T-cell immunity during 13 months in consecutive patients," Leukemia, vol. 36, no. 2, pp. 476-481, 2022.
[14]
I. Lauren et al., "Long-term SARS-CoV-2-specific and cross-reactive cellular immune responses correlate with humoral responses, disease severity, and symptomatology," Immunity, Inflammation and Disease, vol. 10, no. 4, 2022.
[15]
U. Marking et al., "Duration of SARS-CoV-2 Immune Responses Up to Six Months Following Homologous or Heterologous Primary Immunization with ChAdOx1 nCoV-19 and BNT162b2 mRNA Vaccines," Vaccines, vol. 10, no. 3, pp. 359, 2022.
[16]
S. Havervall et al., "Impact of SARS-CoV-2 infection on vaccine-induced immune responses over time," Clinical & Translational Immunology (CTI), vol. 11, no. 4, 2022.
[17]
K. Asplund Högelin et al., "B-cell repopulation dynamics and drug pharmacokinetics impact SARS-CoV-2 vaccine efficacy in anti-CD20-treated multiple sclerosis patients," European Journal of Neurology, vol. 29, no. 11, pp. 3317-3328, 2022.
[18]
M. Malm et al., "Harnessing secretory pathway differences between HEK293 and CHO to rescue production of difficult to express proteins," Metabolic engineering, vol. 72, pp. 171-187, 2022.
[19]
S. Appelberg et al., "A universal SARS-CoV DNA vaccine inducing highly cross-reactive neutralizing antibodies and T cells," EMBO Molecular Medicine, vol. 14, no. 10, 2022.
[20]
S. Havervall et al., "Anti-Spike Mucosal IgA Protection against SARS-CoV-2 Omicron Infection," New England Journal of Medicine, vol. 387, no. 14, pp. 1333-1336, 2022.
[21]
J. Garousi et al., "Experimental HER2-Targeted Therapy Using ADAPT6-ABD-mcDM1 in Mice Bearing SKOV3 Ovarian Cancer Xenografts : Efficacy and Selection of Companion Imaging Counterpart," Pharmaceutics, vol. 14, no. 8, 2022.
[22]
S. Havervall et al., "SARS-CoV-2 induces a durable and antigen specific humoral immunity after asymptomatic to mild COVID-19 infection," PLOS ONE, vol. 17, no. 1, pp. e0262169-e0262169, 2022.
[23]
S. Havervall et al., "Robust humoral and cellular immune responses and low risk for reinfection at least 8 months following asymptomatic to mild COVID-19," Journal of Internal Medicine, vol. 291, no. 1, pp. 72-80, 2022.
[24]
K. Healy et al., "Salivary IgG to SARS-CoV-2 indicates seroconversion and correlates to serum neutralization in mRNA-vaccinated immunocompromised individuals," MED, vol. 3, no. 2, pp. 137-153, 2022.
[25]
M. Jönsson et al., "CaRA – A multi-purpose phage display library for selection of calcium-regulated affinity proteins," New Biotechnology, vol. 72, pp. 159-167, 2022.
[26]
K. Blom et al., "Immune responses after omicron infection in triple-vaccinated health-care workers with and without previous SARS-CoV-2 infection," The Lancet - Infectious diseases, vol. 22, no. 7, pp. 943-945, 2022.
[27]
C. Ekblad et al., "Polypeptides based on a scaffold," us 11505576 (2022-11-22), 2022.
[28]
S. Mravinacová et al., "A cell-free high throughput assay for assessment of SARS-CoV-2 neutralizing antibodies," New Biotechnology, vol. 66, pp. 46-52, 2022.
[29]
H. Schwarz et al., "Integrated continuous biomanufacturing on pilot scale for acid-sensitive monoclonal antibodies," Biotechnology and Bioengineering, 2022.
[30]
V. Tolmachev et al., "Direct In Vivo Comparison of Tc-99m-Labeled Scaffold Proteins, DARPin G3 and ADAPT6, for Visualization of HER2 Expression and Monitoring of Early Response for Trastuzumab Therapy," International Journal of Molecular Sciences, vol. 23, no. 23, 2022.
[31]
K. M. Elfstrom et al., "Differences in risk for SARS-CoV-2 infection among healthcare workers," Preventive Medicine Reports, vol. 24, 2021.
[32]
S. M. Mangsbo et al., "An evaluation of a FluoroSpot assay as a diagnostic tool to determine SARS-CoV-2 specific T cell responses," PLOS ONE, vol. 16, no. 9, 2021.
[33]
P. Bergman et al., "Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a prospective open-label clinical trial," EBioMedicine, vol. 74, pp. 103705, 2021.
[34]
O. Bragina et al., "Phase I Study of Tc-99(m)-ADAPT6, a Scaffold Protein-Based Probe for Visualization of HER2 Expression in Breast Cancer," Journal of Nuclear Medicine, vol. 62, no. 4, pp. 493-499, 2021.
[35]
J. Dillner et al., "High Amounts of SARS-CoV-2 Precede Sickness Among Asymptomatic Health Care Workers," The Journal of Infectious Diseases, vol. 224, no. 1, pp. 14-20, 2021.
[36]
M. Hedhammar, J. Nilvebrant and S. Hober, "Zbasic : A Purification Tag for Selective Ion-Exchange Recovery," in Protein Downstream Processing : Design, Development, and Application of High and Low-Resolution Methods, : Humana Press, 2021, pp. 149-158.
[37]
J. Scheffel, S. Kanje and S. Hober, "ZCa : A protein A-derived domain with calcium-dependent affinity for mild antibody purification," in Methods in Molecular Biology, NaNth ed. : Humana Press Inc., 2021, pp. 245-249.
[38]
J. Nilvebrant, M. Åstrand and S. Hober, "An orthogonal fusion tag for efficient protein purification," in Methods in Molecular Biology, NaNth ed. : Springer Nature, 2021, pp. 159-166.
[39]
J. Garousi et al., "Radionuclide therapy using ABD-fused ADAPT scaffold protein : Proof of Principle," Biomaterials, vol. 266, 2021.
[40]
K. A. Högelin et al., "Development of humoral and cellular immunological memory against SARS-CoV-2 despite B cell depleting treatment in multiple sclerosis," iScience, vol. 24, no. 9, 2021.
[41]
S. Havervall et al., "Antibody responses after a single dose of ChAdOx1 nCoV-19 vaccine in healthcare workers previously infected with SARS-CoV-2," EBioMedicine, vol. 70, 2021.
[42]
S. Klevebro et al., "Risk of SARS-CoV-2 exposure among hospital healthcare workers in relation to patient contact and type of care," Scandinavian Journal of Public Health, vol. 49, no. 7, pp. 707-712, 2021.
[43]
E. von Witting, S. Hober and S. Kanje, "Affinity-Based Methods for Site-Specific Conjugation of Antibodies," Bioconjugate chemistry, vol. 32, pp. 1515-1524, 2021.
[44]
S. Hassan et al., "SARS-CoV-2 infections amongst personnel providing home care services for older persons in Stockholm, Sweden," Journal of Internal Medicine, vol. 290, no. 2, pp. 430-436, 2021.
[45]
S. Havervall et al., "Symptoms and Functional Impairment Assessed 8 Months After Mild COVID-19 Among Health Care Workers," Journal of the American Medical Association (JAMA), vol. 325, pp. 2015, 2021.
[46]
K. A. Hogelin et al., "Impact of B-cell depleting treatments on development of humoral and cellular immunological memory against SARS-CoV-2," Multiple Sclerosis Journal, vol. 27, no. 2_SUPPL, pp. 348-348, 2021.
[47]
J. Garousi et al., "Targeting HER2 Expressing Tumors with a Potent Drug Conjugate Based on an Albumin Binding Domain-Derived Affinity Protein," Pharmaceutics, vol. 13, no. 11, pp. 1847, 2021.
[48]
J. Dillner et al., "Antibodies to SARS-CoV-2 and risk of past or future sick leave," Scientific Reports, vol. 11, no. 1, 2021.
[49]
H. Alkharaan et al., "Persisting Salivary IgG Against SARS-CoV-2 at 9 Months After Mild COVID-19 : A Complementary Approach to Population Surveys," Journal of Infectious Diseases, vol. 224, no. 3, pp. 407-414, 2021.
[50]
M. Ding et al., "Secretome screening reveals immunomodulating functions of IFNα-7, PAP and GDF-7 on regulatory T-cells," Scientific Reports, pp. 16767, 2021.